Arthritis & Rheumatism
|
|
- Abigail Bond
- 5 years ago
- Views:
Transcription
1 ARTHRITIS & RHEUMATISM Vol. 48, No. 10, October 2003, pp DOI /art American College of Rheumatology EDITORIAL Arthritis & Rheumatism An Official Journal of the American College of Rheumatology and Can We Accurately Predict the Development of Rheumatoid Arthritis in the Preclinical Phase? Darcy S. Majka and V. Michael Holers Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint destruction, which leads to functional decline and disability as well as increased mortality (1 4). A growing body of evidence indicates that joint destruction and functional decline are improved by early therapeutic intervention (5,6). In addition, the risk of mortality is decreased in patients with RA who present early in the disease course, strongly suggesting that earlier diagnosis and treatment may have substantial long-term benefits (7). Because asymptomatic synovitis has been identified prior to major clinical manifestations of RA (8,9), prevention of disability in RA might be even more successful if interruption of the process underlying joint destruction were carried out in the early phase of the disease or even before the disease is clinically evident, rather than when destructive synovitis is well established. The article by Rantapää-Dahlqvist et al published in this issue of Arthritis & Rheumatism (10) demonstrates that antibodies to cyclic citrullinated peptide (CCP) as well as rheumatoid factor (RF) can be identified in stored serum from individuals who later develop clinically apparent RA. The authors conclude that such autoantibodies may be predictive of the future development of RA in asymptomatic individuals. This article raises the question of whether we can accurately identify Supported by NIH grant 1-U19-AI Dr. Majka s work was supported by a Physician Scientist Development award from the Arthritis Foundation/American College of Rheumatology Research and Education Foundation. Darcy S. Majka, MD, V. Michael Holers, MD: University of Colorado Health Sciences Center, Denver. Address correspondence and reprint requests to V. Michael Holers, MD, Division of Rheumatology, University of Colorado Health Sciences Center, Box B115, 4200 East Ninth Avenue, Denver, CO michael.holers@uchsc.edu. Submitted for publication April 28, 2003; accepted May 9, individuals at risk for the development of RA during the preclinical phase of disease. If such an endeavor could be accomplished, then primary prevention or, at a minimum, very early intervention strategies could be implemented. Over the last 60 years, several autoantibody systems have been proposed as diagnostic and/or prognostic tools for RA, but only the presence of RF is included as a serologic criterion in the American College of Rheumatology (formerly, the American Rheumatism Association) classification criteria for RA (11). However, the anti-ccp autoantibody system has received a great deal of study recently and may have an important role in providing supportive evidence for a diagnosis of RA. The anti-ccp autoantibody system includes a group of autoantibodies with shared reactivity to proteins containing arginine residues that have been modified to citrulline. These autoantibodies include antiperinuclear factor (APF), antikeratin antibody (AKA), antifilaggrin antibody (AFA), and anti-ccp antibodies. The APF autoantibody was first described in 1964 (12,13). This antibody binds to perinuclear keratohyalin granules in the cytoplasm of buccal mucosa cells. The sensitivity of APF in RA ranges from 49% to 87%, but the specificity is only moderate, since the test result is positive in sera from individuals with other autoimmune diseases, including systemic sclerosis, autoimmune thyroiditis, and systemic lupus erythematosus (SLE) (12). AKA, an autoantibody reactive with a similar antigen, was first described in 1979 (14). AKA binds to the stratum corneum of rat esophagus and has a sensitivity of 59% and a specificity of 100% (12,15). APF and AKA are measured by indirect immunofluorescence, which makes testing and interlaboratory comparisons of the results difficult. In part because of these problems, neither test has gained widespread clinical application (16). 2701
2 2702 MAJKA AND HOLERS More recently, the epithelial antigen recognized by AKA (17,18) and APF (19) has been determined to be the protein filaggrin and, due to the apparent identity between APF and AKA, it has been proposed that these autoantibodies be renamed antifilaggrin autoantibodies (19). Filaggrin, or filament-aggregating protein, is formed during late differentiation of mammalian epithelial cells (20) and is involved in the regulation of cytokeratin intermediate filament aggregation. Filaggrin is formed as a precursor protein, profilaggrin, with filaggrin repeats that are released by proteolytic cleavage during cell differentiation. Simultaneously, a number of the arginine residues in filaggrin are converted to citrulline as a posttranslational modification mediated by the enzyme peptidyl arginine deiminase. Importantly, the conversion of arginine to citrulline is required for AFA recognition of the filaggrin peptides (20,21). Filaggrin has only been detected in squamous epithelial cells (20). However, AFAs have been identified in the synovial membrane and are synthesized by plasma cells in the rheumatoid pannus (22). This has led to the hypothesis that autoantibodies against citrullinated filaggrin are cross-reactive with a citrullinated peptide within the synovium (20). Consistent with this possibility, target epitopes identified as citrullinated and -chains of fibrin exist in the rheumatoid synovial membrane (23). Since citrullinated filaggrin does not exist in the joint, and is therefore unlikely to be the putative RA-specific autoantigen, van Venrooij and Pruijn recently proposed that this autoantibody system be called anti citrullinated protein antibodies (24). Those authors hypothesized that citrullination of proteins within the inflamed rheumatoid joint may occur as a result of apoptosis (24). Paralleling investigations to identify the target autoantigens of this system have been efforts to develop robust and clinically useful serologic tests. Paimela et al (25) used filaggrin purified from human skin as the antigen in an enzyme-linked immunosorbent assay (ELISA) to evaluate serum from patients with established RA; the reported sensitivity of this assay was only 54%. Schellekens et al (20,26) designed a synthetic cyclic citrullinated peptide with deiminated arginines for use as the antigen in an ELISA for anti-ccp autoantibodies. This assay demonstrated an impressive specificity of 98% in sera from patients with established RA and 96% in sera from patients with early RA. The sensitivity of this anti-ccp ELISA was 68% and 48% in sera from patients with established RA and early RA, respectively (26). RF is the gold standard test for serologic support of a diagnosis of RA but has a specificity of only 90 95%, depending upon the age of the individual tested (12). Therefore, detection of anti-ccp antibodies has the potential to better distinguish early RA from other non-ra inflammatory polyarthritides. Although the sensitivity of anti-ccp antibodies is less than that of RF (68% versus 80% [27]), anti-ccp antibodies have been found in the sera of patients with RF-negative RA (20,26). Consequently, one clinical use of anti-ccp antibody testing could be in combination with RF testing in order to improve the sensitivity of the serologic diagnosis of RA. Additionally, the anti-ccp autoantibody system has been associated with progression to erosive RA and a more severe disease course (26,28,29). Therefore, this autoantibody system may contribute to clinical decision-making regarding therapy for RA. Importantly, the results reported by Rantapää- Dahlqvist et al (10) suggest that detection of anti-ccp antibodies may also be of value in identifying individuals with RA prior to the onset of symptoms and destructive synovitis. Consistent with this hypothesis, various autoantibodies from the anti-ccp autoantibody system have been observed preclinically. Aho and colleagues (12,15,30) identified preclinical AKA and APF autoantibodies in 20% of stored serum samples from 69 patients who later developed RA. The same group of investigators also showed that the presence of AKA or AFA increased the risk of seropositive RA development 5-fold in individuals with preclinically positive RF (31). In the studies reported by Rantapää-Dahlqvist and colleagues, stored serum samples were obtained from individuals with RA that had been previously collected as part of 2 cohorts, the Northern Sweden Health and Disease Study cohort and the Maternity cohort of Northern Sweden. A total of 83 individuals with RA (85% female) as well as matching controls were selected for analysis of samples that had been collected a median of 2.5 years prior to presentation with RA symptoms (i.e., the preclinical phase). Anti-CCP antibodies and RF of all isotypes were detected during the preclinical phase of RA; the prevalence of anti-ccp antibodies, IgG-RF, IgM-RF, and IgA-RF was 33.7%, 16.9%, 19.3%, and 33.7%, respectively. Additionally, 21 samples collected a median of 10.9 years prior to presentation with RA symptoms were tested, but without controls for comparison. The longest intervals predating the onset of RA symptoms were 9 years, 22 years, and 19 years for anti-ccp antibodies, IgA-RF, and IgG/IgM- RF, respectively. Anti-CCP antibodies and IgA-RF had statistically significant odds ratios for the future development of RA in a multivariate conditional logistic regression model, 28.9 ( ) and 11.4 ( ), respectively. Anti-CCP antibodies had a positive predic-
3 EDITORIAL 2703 tive value (PPV) of 82% for the development of RA in this cohort, but the PPV was only 16% when calculated for the general population using an estimated prevalence of RA equal to 1%. While these results are striking, there are several limitations to this study. First, it should be noted that some serum samples were collected during pregnancy, possibly leading to an underestimation of the prevalence of autoantibodies in preclinical RA, given that pregnancy may be protective against the development of new-onset RA. Second, the authors state that seropositivity for anti-ccp persisted in subsequent preclinical samples and that the titer increased until symptoms of RA were manifested. This conclusion cannot be fully evaluated, since there were only 15 subjects from whom 2 preclinical samples were available for testing, and the results of these tests were not reported separately. Furthermore, the comparison appears to be between the overall preclinical mean anti-ccp antibody level and the mean anti-ccp level measured during early RA. Thus, a limitation of this study is that the cohorts lacked the serial serologic specimens necessary for a detailed analysis of the stability and level of preclinical autoantibody seropositivity over time. Third, the limits of the anti- CCP autoantibody system as a screening test in the general population should also be noted. The authors estimate the PPV of anti-ccp antibodies for the future development of RA in the general population to be only 16%. Therefore, in order to use the anti-ccp antibody test to predict the future development of RA, it should be combined with an evaluation for other risk factors for RA, such as genetic predisposition, family history, and the presence of seropositivity for other autoantibodies. This study raises the important clinical issue concerning the identification of a stage of preclinical autoimmunity in RA. An increased understanding of the evolution of preclinical autoimmunity in autoimmune diseases such as type 1 diabetes mellitus (DM) and SLE has recently emerged (32). The current concept is that autoimmune diseases such as type 1 DM and SLE may exhibit 3 phases during their development. The first phase is defined as a state of susceptibility resulting from genetic risk factors, either alone or in combination, that predispose to the loss of self tolerance. The second phase is the transition in an individual with genetic risk to a state of autoreactivity with autoantibody production that is not yet associated with clinically apparent disease that would meet diagnostic or classification criteria. This transition from risk to initial autoimmunity occurs because of the introduction of an environmental factor or perhaps because of the stochastic nature of the immune response. This preclinical autoimmune phase is associated with either the development of one or a small number of autoantibodies and precedes the commonly observed substantial epitope spreading that is associated with major tissue injury. The third phase is the development of clinically apparent disease, which is characterized by extensive immune-mediated tissue destruction. The presence of these 3 disease phases is well established for type 1 DM (33). During the first phase of disease, susceptibility to type 1 DM is conferred by genes in the HLA region and to a smaller extent by genes on other chromosomes (33). Then, genetically predisposed individuals progress to the second phase of disease, with immune-mediated destruction of the pancreatic islet beta cells that normally secrete insulin (33,34). In type 1 DM, autoantibodies against islet cells typically appear by age 5, and the development of multiple autoantibodies is strongly predictive of eventual advancement to clinical disease (33 36). At the point at which an individual progresses to the third phase of disease, displaying clinically apparent diabetes, there has already been a progressive decline in beta cell function, and the majority of beta cells have been damaged or destroyed (33,34). Although this last phase is the one in which the vast majority of patients seek medical care, prevention strategies must focus on identifying patients during earlier phases of disease. There are currently large prospective studies attempting to do just that. For example, the Diabetes and Autoimmunity Study in the Young (DAISY) (37) is a prospective study designed to identify individuals at high risk for the development of type 1 DM so that prophylactic intervention can be applied during the preclinical phase. DAISY investigators have been serially evaluating over time the relatives of probands with Figure 1. Three phases of rheumatoid arthritis (RA) and means of detecting preclinical disease that parallel ongoing studies in other autoimmune diseases, such as type 1 diabetes mellitus and systemic lupus erythematosus. RF rheumatoid factor; anti-ccp anti cyclic citrullinated peptide.
4 2704 MAJKA AND HOLERS type 1 DM as well as a newborn general population cohort since 1994 in order to quantify the risk of developing type 1 DM. Staging consists of genetic screening for HLA haplotypes conveying increased disease risk and immunologic screening for autoantibodies reactive with islet cells and insulin. This staging can predict risk for the development of type 1 DM with remarkably accurate precision (37,38). Moreover, some at-risk individuals are currently being studied in a large multicenter primary prevention trial called the Diabetes Prevention Trial Type 1 Diabetes (35) whose goal is to prevent or delay the development of overt diabetes. Interventions used by the Diabetes Prevention Trial have included the administration of parenteral or oral insulin. The results of parenteral insulin therapy were disappointing, despite several pilot studies indicating successful delay of disease development with insulin therapy (38 40). However, oral insulin trials are still in progress. A similar study, the European Nicotinamide Diabetes Intervention Trial (ENDIT), is also addressing whether nicotinamide will reduce the rate of progression to DM in at-risk relatives (41). In addition, treatment with tolerizing, nondepleting anti-cd3 antibodies has been successful in delaying disease onset in animal models, and this intervention has been proposed as a potential preventive measure for the clinical onset of hyperglycemia (34,42). Important to studies of the rheumatic diseases, Arbuckle et al (43) have published results of a retrospective case control study in which 55% of 133 SLE patients were found to have anti double-stranded DNA (anti-dsdna) autoantibodies in stored serum samples up to 9.3 years before the diagnosis of clinical SLE (43). The mean onset of autoantibody positivity was 2.7 years prior to disease diagnosis. Applying the hypothesis of 3 distinct phases of autoimmune disease to SLE, it is likely that an individual with an underlying genetic predisposition for the development of SLE is exposed to some triggering factor, such as estrogen, ultraviolet light, or an infectious agent, that stimulates the production of antidsdna autoantibodies. Eventually, with epitope spreading and time, this individual develops clinical symptoms of SLE. The data presented by Rantapää-Dahlqvist et al provide an increased understanding of the preclinical phase of RA. Individuals carrying the shared epitope of HLA DR alleles have a well-defined increase in relative risk for the development of RA (44,45). Such predisposed individuals may at some point encounter an environmental factor, such as an infection, hormonal influence, or tobacco exposure, which leads to the production of preclinical autoantibodies, such as anti- CCP or RF (Figure 1). Eventually, in a subset of at-risk individuals, clinical symptoms develop, and the individual is diagnosed as having RA. It remains to be determined whether the early appearance of RF and anti- CCP autoantibodies in RA represents a primary loss of tolerance to self antigens or a secondary response to subclinical tissue injury with exposure to novel or abundant autoantigens. While the data presented by Rantapää-Dahlqvist et al provide insight into the preclinical phase of RA, long-term prospective studies similar to those in type 1 DM are needed in order to more definitively characterize the evolution of this autoimmune disease. It is possible that with such a study, the additive effect of individual contributors such as genetic predisposition, environmental exposures, and possible loss of self tolerance can be more fully understood. Such a study would also allow for the more accurate identification of the onset of clinical RA as well as the stability of autoantibodies over time so that the predictive value of such autoantibodies could be more precisely defined. Nonetheless, this retrospective study and others that identify the preclinical presence of autoantibodies in RA may provide a major breakthrough in our understanding of this disease and eventually in its clinical management. Further strategies designed to identify individuals at high risk for the development of RA may allow for the introduction of prevention or very early treatment strategies with the potential to greatly affect the morbidity and mortality of this very debilitating disease. REFERENCES 1. Fuchs HA, Sergent JS. Rheumatoid arthritis: the clinical picture. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins; p Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: mediation by helplessness scale score. Arthritis Care Res 1996;9: Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to Scand J Rheumatol 2000;29: Gabriel SE, Crowson CS, O Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26: Van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with second-line antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996;124: Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40: Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality
5 EDITORIAL 2705 outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25: Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, t Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41: Conaghan PG, Wakefield RJ, O Connor P, Gibbon WW, Brown C, McGonagle D, et al. MCPJ assessment in early RA: a comparison between x-ray, MRI, high-resolution ultrasound and clinical examination [abstract]. Arthritis Rheum 1998;41 Suppl 9:S Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48: Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum 1994;23: Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23: Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979;2: Kurki P, Aho K, Palosuo T, Heliövaara M. Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35: Van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4: Simon M, Girbal E, Sebbag M, Gomès-Daudrix V, Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called antikeratin antibodies, autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993;92: Girbal E, Sebbag M, Gomès-Daudrix V, Simon M, Vincent C, Serre G. Characterisation of the rat oesophagus epithelium antigens defined by the so-called antikeratin antibodies, specific for rheumatoid arthritis. Ann Rheum Dis 1993;52: Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95: Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritisspecific autoantibodies. J Clin Invest 1998;101: Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162: Masson-Bessière C, Sebbag M, Durieux JJ, Nogueira L, Vincent E, Girbal-Neuhauser, Durroux R, et al. In the rheumatoid pannus, antifilaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000;119: Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the - and -chains of fibrin. J Immunol 2001;166: Van Venrooij WJ, Pruijn GJM. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000;2: Paimela L, Palosuo T, Aho K, Lukka M, Kurki P, Leirisalo-Repo M, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2000;60: Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43: Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91: Meyer O, Combe B, Elias A, Benali K, Clot J, Sany J, et al. Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis 1997;56: Munoz-Fernandez S, Avarez-Doforno R, Gonzalez-Tarrio JM, Balsa A, Richi P, Rontan G, et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis. J Rheumatol 1999; 26: Aho K, von Essen R, Kurki P, Palosuo T, Heliövaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20: Aho K, Palosuo T, Heliövaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within normal range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000;27: Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001;108: Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of preinsulin dependent diabetes. Annu Rev Med 1998;49: Gale EAM. Can we change the course of beta-cell destruction in type 1 diabetes? N Engl J Med 2002;346: Diabetes Prevention Trial Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346: Gardner SG, Gale EAM, Williams AJK, Gillespie KM, Lawrence KE, Bottazzo GF, et al. Progression to diabetes in relatives with islet autoantibodies: is it inevitable? Diabetes Care 1999;22: Robles DT, Eisenbarth GS, Wang T, Erlich HA, Bugawan TL, Babu SR, et al. Identification of children with early onset and high incidence of anti-islet autoantibodies. Clin Immunol 2002;102: Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993;341: Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993;9: Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998;41: Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001;14 Suppl 1: Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346: Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsdna autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001;54: Nepom GT, Nepom BS. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am 1992;18: Jawaheer D, Gregersen PK. Rheumatoid arthritis: the genetic components. Rheum Dis Clin North Am 2002;28:1 15.
Diagnostic Performances of Anti-Cyclic Citrullinated Peptides Antibody and Antifilaggrin Antibody in Korean Patients with Rheumatoid Arthritis
J Korean Med Sci 2005; 20: 473-8 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Diagnostic Performances of Anti-Cyclic Citrullinated Peptides Antibody and Antifilaggrin Antibody in Korean
More informationAnti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis
Q J Med 2007; 100:193 201 doi:10.1093/qjmed/hcm015 Review Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis T.B. NIEWOLD, M.J. HARRISON and S.A. PAGET From the Department
More informationAnticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis
REVIEW Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis W.J. van Venrooij 1*, J.M. Hazes 2, H. Visser 3 1 Department of Biochemistry
More informationUse of Serological markers for evaluation of patients with Rheumatoid arthritis
ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 61-66 http://www.ijcmas.com Original Research Article Use of Serological markers for evaluation of patients with Rheumatoid arthritis G. Sucilathangam*, G.
More informationClinic of Neurology, Carol Davila University of Medicine and Pharmacy, Colentina Clinical Hospital, Bucharest, Romania c
Mædica - a Journal of Clinical Medicine EDITORIALS Autoimmunity to cyclic citrullinated peptide in rheumatoid arthritis Manole COJOCARU, MD, PhD a, Inimioara Mihaela COJOCARU MD, PhD b, Isabela SILOSI
More informationDejan Spasovski * University Clinic of Rheumatology, Sc Ciryl and Methodius University, Skopje, Republic of Macedonia.
IBBJ Summer 2016, Vol 2, No 3 Original Article Frequency and Accuracy of Anti-Citrullinated Protein Antibodies, Prognostic Evaluation in Overall Developing to Erosive Disease in Patients with Psoriatic
More informationR ecent papers have highlighted the early treatment of
415 EXTENDED REPORT Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases S Dubucquoi, E Solau-Gervais, D Lefranc, L Marguerie, J Sibilia, J Goetz,
More informationCCPoint CCPoint 20 US
CCPoint CCPoint 20 US CCPoint A visually read, qualitative rapid lateral flow test for the detection of Rheumatoid Arthritis specific autoantibodies (anti-ccp) (Cat. No. CCPoint 20 US) For use by trained
More informationThe Role of Anti-Mutated Citrullinated Vimentin Antibodies in the Diagnosis of Early Rheumatoid Arthritis
The Role of Anti-Mutated Citrullinated Vimentin Antibodies in the Diagnosis of Early Rheumatoid Arthritis XIA LIU, RULIN JIA, JINXIA ZHAO, and ZHANGUO LI ABSTRACT. Objective. Anti-mutated citrullinated
More informationR heumatoid arthritis (RA) is a common rheumatic disease
870 EXTENDED REPORT Clinical utility of the anti-ccp assay in patients with rheumatic diseases DMLee,PHSchur... See end of article for authors affiliations... Correspondence to: Professor P H Schur, Brigham
More informationDiagnostic and prognostic values of antikeratin antibodies (AKA) and collagen III propeptides (PIIINP) in juvenile rheumatoid arthritis.
Egypt J Pediatr Allergy Immunol 2003; 1(1): 40-45. Original article Diagnostic and prognostic values of antikeratin antibodies (AKA) and collagen III propeptides (PIIINP) in juvenile rheumatoid arthritis.
More informationC itrulline is an amino acid that is post-translationally
443 EXTENDED REPORT Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? M-K Koivula, S Åman, A Karjalainen,
More informationAutoantibodies in rheumatoid arthritis and their clinical significance Günter Steiner and Josef Smolen
Available online http://arthritis-research.com/content/4/s2/s1 Autoantibodies in rheumatoid arthritis and their clinical significance Günter Steiner and Josef Smolen Vienna General Hospital, University
More informationAnti-CCP antibodies in children with Juvenile Idiopathic Arthritis (JIA) diagnostic and clinical significance
Clinical immunology Anti-CCP antibodies in children with Juvenile Idiopathic Arthritis (JIA) diagnostic and clinical significance JOANNA LIPIÑSKA 1, EL BIETA SMOLEWSKA 1, 2, HENRYKA BRÓZIK 2, JERZY STAÑCZYK
More informationR heumatoid arthritis (RA) is a chronic inflammatory
1587 EXTENDED REPORT Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationAssociation of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes
International Journal of Medicine and Medical Sciences Vol. () pp. 21-214, June 211 Available online http://www.academicjournals.org/ijmms ISSN 2-972 211 Academic Journals Full Length Research Paper Association
More informationSynovial Fluid Levels Of Anti-Cyclic Citrullinated Peptide Antibodies And Iga Rheumatoid Factor In Rheumatoid Arthritis And Osteoarthritis By
Synovial Fluid Levels Of Anti-Cyclic Citrullinated Peptide Antibodies And Iga Rheumatoid Factor In Rheumatoid Arthritis And Osteoarthritis By Yasser Ezzat*, Abeer Nabil**, Hussein El-Dakrouni** and Rania
More informationaddress: (A. Das), (C. Phukan), (C. Baruah)
International Journal of Immunology 2016; 4(5): 27-34 http://www.sciencepublishinggroup.com/j/iji doi: 10.11648/j.iji.20160405.11 ISSN: 2329-177X (Print); ISSN: 2329-1753 (Online) A Study on the Importance
More informationAnti-CCP: History and its usefulness
Clinical & Developmental Immunology, June 2005; 12(2): 131 135 Anti-CCP: History and its usefulness M. HEROLD, V. BOESER, E. RUSSE, & W. KLOTZ Rheumatology Unit, Clinical Department of General Internal
More informationCitrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis specific Autoantibodies
Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis specific Autoantibodies Gerard A. Schellekens,* Ben A.W. de Jong,* Frank H.J. van den Hoogen, Leo B.A.
More informationARD Online First, published on May 1, 2007 as /ard
ARD Online First, published on May 1, 2007 as 10.1136/ard.2006.062919 EXTENDED REPORT Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict
More informationDevelopment of the Anti Citrullinated Protein Antibody Repertoire prior to the Onset of Rheumatoid Arthritis
Development of the Anti Citrullinated Protein Antibody Repertoire prior to the Onset of Rheumatoid Arthritis Lotte A. van de Stadt 1, Margret H. M. T. de Koning Rob J. van de Stadt Gertjan Wolbink 1, Ben
More informationG. Lakos 1, L. Soós 2, A. Fekete 1, Z. Szabó 2, M. Zeher 3, I.F. Horváth 3, K. Dankó 3, A. Kapitány 1, A. Gyetvai 1, G. Szegedi 4, Z.
Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope G. Lakos 1, L. Soós 2, A.
More informationUnderstanding Autoimmune Diseases: Evolving Issues. Alvina D. Chu, M.D. April 23, 2009
Understanding Autoimmune Diseases: Evolving Issues Alvina D. Chu, M.D. April 23, 2009 Objectives Define the key pathogenic characteristics of: Type I diabetes mellitus Multiple sclerosis Rheumatoid arthritis
More informationDiagnostic and prognostic serological analyses in RA
9/9/ Diagnostic and prognostic serological analyses in RA Johan Rönnelid Clinical Immunology and Transfusion medicine Akademiska sjukhuset, Uppsala Department of Immunology, Genetics and Pathology Uppsala
More information1996 British Society for Rheumatology
British Journal of Rheumatology 1996;35:62O-624 DIAGNOSTIC VALUE OF ANTI- ANTIBODY, ANTTKERATIN ANTIBODY, ANTTPERINUCLEAR FACTOR AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH
More informationCitation for published version (APA): Cantaert, T. (2008). How is autoimmunity against citrullinated proteins regulated?
UvA-DARE (Digital Academic Repository) How is autoimmunity against citrullinated proteins regulated? Cantaert, T. Link to publication Citation for published version (APA): Cantaert, T. (2008). How is autoimmunity
More informationAssociations between Serum Anti-CCP Antibody, Rheumatoid Factor Levels and HLA-DR4 Expression in Hungarian Patients with Rheumatoid Arthritis
Associations between Serum Anti-CCP Antibody, Rheumatoid Factor Levels and HLA-DR4 Expression in Hungarian Patients with Rheumatoid Arthritis Anikó Kapitány MD PhD 1,3, *, Zoltán Szabó MD PhD 2, *, Gabriella
More informationORIGINAL INVESTIGATION. C-Reactive Protein in the Prediction of Rheumatoid Arthritis in Women
ORIGINAL INVESTIGATION C-Reactive Protein in the Prediction of Rheumatoid Arthritis in Women Nancy A. Shadick, MD, MPH; Nancy R. Cook, ScD; Elizabeth W. Karlson, MD; Paul M Ridker, MD, MPH; Nancy E. Maher,
More informationRheumatology function tests: Quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases
Rheumatology function tests: Quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases T. Pincus Division of Rheumatology and Immunology, Department
More informationChapter 3. ANNALS OF THE RHEUMATIC DISEASES 2008; 67(9): doi: /ard
The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-ccp), and its effect on anti- CCP levels Wouter H Bos Jennie Ursum Niek de Vries Geertje M Bartelds
More informationKEY WORDS anti-cyclic citrullinated peptide antibodies, palindromic rheumatism, rheumatoid arthritis, sonographic findings
O R I G I N A L A R T I C L E Predicting the Progression of Palindromic Rheumatism to Rheumatoid Arthritis: The Role of Ultrasonography and Anti-cyclic Citrullinated Peptide Antibodies Hsin-Hua Chen 1,2,3,
More informationCommentary Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis Erik R Vossenaar and Walther J van Venrooij
Commentary Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis Erik R Vossenaar and Walther J van Venrooij Department of Biochemistry, University of Nijmegen, Nijmegen, The
More informationStudy of Peptidyl Arginine Deiminases 4 (PAD 4) Antibodies in Rheumatoid Arthritis Patients
Original Article Study of Peptidyl Arginine Deiminases 4 (PAD 4) Antibodies in Rheumatoid Arthritis Patients Darwish A. El-Hallous 1, Nevine Mohannad 2, Maher A. Kamel 3, El-Sayed H. Radwan 4 Departments
More informationLABORATORY STANDARDS IN DIAGNOSIS AND THERAPY MONITORING OF RHEUMATOID ARTHRITIS
LABORATORY STANDARDS IN DIAGNOSIS AND THERAPY MONITORING OF RHEUMATOID ARTHRITIS Andrea Tešija- Kuna, M.Sc. Clinical Institute of Chemistry, School of Medicine University of Zagreb & Sestre milosrdnice
More informationPATHOGENESIS OF RHEUMATOID ARTHRITIS
PATHOGENESIS OF RHEUMATOID ARTHRITIS Division of Rheumatology Department of Internal Medicine College of Medicine Seoul National University Seoul National University Bundang Hospital Yun Jong Lee Rheumatoid
More informationAdvances in Laboratory Testing for Rheumatic Diseases Updates in Testing for Rheumatic Diseases. The ABIM s view of rheumatologic lab testing
The black hole of medical knowledge: An internist s view of rheumatologic lab tests Advances in Laboratory Testing for Rheumatic Diseases 2010 Jonathan Graf, M.D. Assistant Clinical Professor of Medicine
More informationOriginal Article. Abstract
Original Article Diagnostic accuracy of antinuclear antibodies and anti-double stranded DNA antibodies in patients of systemic lupus erythematosus presenting with dermatological features Attiya Tareen*,
More informationA retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis
A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis S. Aotsuka 1, M. Okawa-Takatsuji 1, K. Nagatani 1, C. Nagashio
More informationAUTOANTIBODIES PRECEDING AUTOIMMUNE DISEASES
AUTOANTIBODIES PRECEDING AUTOIMMUNE DISEASES STUDY GROUP - AUTOANTIBODY STANDARDIZING COMMITTEE Washington, November 12th 2012 Luis Eduardo Coelho Andrade, M.D, Ph.D. Associate Professor Rheumatology Division
More informationAnti-Citrullinated Protein / Peptide Antibodies in Rheumatoid Arthritis
EDITION 1 2007 n Clinical Background Rheumatoid Arthritis Getting the Best Outcome n Diagnostic Markers Anti-Citrullinated Protein / Peptide Antibodies in Rheumatoid Arthritis n Practice Point Prediction
More informationPROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1995;34:1146-1150 PROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS L. PAEVDELA, T. PALOSUO,* M. LEIRISALO-REPO,t T. HELVE
More informationRheumatologic Lab Tests
Rheumatologic Lab Tests What the Practitioner Needs to Know Mary Nakamura M.D. 2008 Rheumatologic Lab Tests Are rarely diagnostic of any specific disease If you do not have in mind a rheumatologic disease
More informationLisbeth Ärlestig, 1 Mohammed Mullazehi, 2 Heidi Kokkonen, 1 Joacim Rocklöv, 1 Johan Rönnelid, 2 Solbritt Rantapää Dahlqvist 1 EXTENDED REPORT
An additional fi gure is published online only. To view the fi les, please visit the journal online (http://ard.bmj.com/ content/71/6.toc). 1 Departments of Public Health and Clinical Medicine/ Rheumatology
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationIbrar Ahmed, Amjad Taqweem, Zafar Ali, Intekhab Alam, Amjad Mehboob ABSTRACT
ORIGINAL ARTICLE ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES AS A TOOL IN DIFFRENTIATING PATIENTS WITH RHEUMATOID ARTHRITIS FROM PATIENTS WITH CHRONIC HEPATITIS C INFECTION-ASSOCIATED POLYARTICULAR INVOLVEMENT
More informationR heumatoid arthritis is one of the most common immune
587 EXTENDED REPORT A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population L Caponi, E Petit-Teixeira, M Sebbag, F Bongiorni, S Moscato,
More informationThe Pathogenesis of Bone Erosions in RA FULL VERSION
The Pathogenesis of Bone Erosions in RA FULL VERSION 1 Key Learning Objectives Understand the role of osteoclasts in normal bone remodeling Comprehend the key processes in pathologic osteoclast functions
More informationPATHOGENESIS OF RHEUMATOID ARTHRITIS
PATHOGENESIS OF RHEUMATOID ARTHRITIS Division of Rheumatology Department of Internal Medicine College of Medicine Seoul National University Seoul National University Bundang Hospital Yun Jong Lee Rheumatoid
More informationAntibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis
Related Commentary, page 869 Research article Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis Kristine A. Kuhn, 1 Liudmila Kulik, 2 Beren Tomooka, 3,4
More informationLack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population
Lack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population J. Zhu 1 *, F. He 2 *, D.D. Zhang 2 *, J.Y. Yang 2, J. Cheng 1, R. Wu 1, B. Gong 2, X.Q. Liu
More informationAnti-CCP2 testing. The Gold Standard in Diagnosis of Rheumatoid Arthritis. 1 of 11 P a g e
Anti-CCP2 testing The Gold Standard in Diagnosis of Rheumatoid Arthritis 1 of 11 P a g e 2014-01- 07 Contents 1. Scope... 3 2. CCP2: Definition and Background... 3 3. The market for CCP2 assays... 3 4.
More informationComparison of Anti CCP Positivity in RA and Other Arthritic Patients Including Connective Tissue Disorders
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 2461-2473 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.291
More informationHumoral autoimmune response against specific collagen type II epitopes in Bulgarian patients with rheumatoid arthritis
Tsvetelina Batsalova 1 Petya Ivanova 1 Plamka Antova 2 Balik Dzhambazov 1 Humoral autoimmune response against specific collagen type II epitopes in Bulgarian patients with rheumatoid arthritis Authors
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationFilipe Barcelos, * Isabel Abreu, ** José Vaz Patto, * Hélder Trindade, ** Ana Teixeira * Abstract. Introduction
ARTIGO ORIGINAL ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES AND RHEUMATOID FACTOR IN SJÖGREN' S SYNDROME Filipe Barcelos, * Isabel Abreu, ** José Vaz Patto, * Hélder Trindade, ** Ana Teixeira * Abstract
More informationReceived: 23 Mar 2005 Revisions requested: 18 Apr 2005 Revisions received: 22 Apr 2005 Accepted: 11 May 2005 Published: 14 Jun 2005
Available online http://arthritis-research.com/content/7/5/r949 Vol 7 No 5 Research article Open Access Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/18551 holds various files of this Leiden University dissertation. Author: Woude, Diane van der Title: Anti-citrullinated protein antibodies (ACPA) in rheumatoid
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationReview Article A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis
SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2011, Article ID 815038, 18 pages doi:10.4061/2011/815038 Review Article A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide
More informationAntibodies Against Citrullinated Vimentin in Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 58, No. 1, January 2008, pp 36 45 DOI 10.1002/art.23188 2008, American College of Rheumatology Antibodies Against Citrullinated Vimentin in Rheumatoid Arthritis Higher Sensitivity
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationSelf-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance
Autoimmunity Self-tolerance Lack of immune responsiveness to an individual s own tissue antigens Central Tolerance Peripheral tolerance Factors Regulating Immune Response Antigen availability Properties
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationCommand PLA, Chengdu, PR China. Accepted 1 March, 2011
Scientific Research and Essays Vol. 6(12), pp. 2465-2469, 18 June, 2011 Available online at http://www.academicjournals.org/sre DOI: 10.5897/SRE10.1042 ISSN 1992-2248 2011 Academic Journals Full Length
More informationThe association of anti-ccp antibodies with disease activity in rheumatoid arthritis
Rheumatol Int (2008) 28:965 970 DOI 10.1007/s00296-008-0570-3 ORIGINAL ARTICLE The association of anti-ccp antibodies with disease activity in rheumatoid arthritis Münevver Serdaroflu Haoim ÇakÂrbay Orhan
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationP soriatic arthritis is a type of inflammatory joint disease in
1145 EXTENDED REPORT Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis B Vander Cruyssen, I E A Hoffman, H Zmierczak, M Van den Berghe, E Kruithof, L De Rycke, H Mielants,
More informationPredictors of Disease Onset and Progression in Early Rheumatoid Arthritis
UMEÅ UNIVERSITY MEDICAL DISSERTIONS New Series No 1001-ISSN 0346-6612-ISBN 91-7264-003-0 From the Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden Predictors
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/18551 holds various files of this Leiden University dissertation. Author: Woude, Diane van der Title: Anti-citrullinated protein antibodies (ACPA) in rheumatoid
More informationPolymorphisms of interleukin-31 are associated with anti-ccp levels in females with rheumatoid arthritis
c Indian Academy of Sciences RESEARCH NOTE Polymorphisms of interleukin-31 are associated with anti-ccp levels in females with rheumatoid arthritis JI-IN YU 1, YOUNG-RAN PARK 2, SHIN-SEOK LEE 3 and SOO-CHEON
More informationTopical Reviews An overview of current research and practice in rheumatic disease
R E P O R T S O N T H E R H E U M A T I C D I S E A S E S S E R I E S 5 Topical Reviews An overview of current research and practice in rheumatic disease Medical Editor: Ade Adebajo Production Editor:
More informationTargeted Ultrasound of the Fifth Metatarsophalangeal Joint in an Early Inflammatory Arthritis Cohort
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 61, No. 7, July 15, 2009, pp 1004 1008 DOI 10.1002/art.24564 2009, American College of Rheumatology CONTRIBUTIONS FROM THE FIELD Targeted Ultrasound
More informationAssociation of rheumatoid factors and antifilaggrin antibodies with severity of erosions in rheumatoid arthritis
Rheumatology 2000;39:1082 1088 Association of rheumatoid factors and antifilaggrin antibodies with severity of erosions in rheumatoid arthritis S. Bas, T. V. Perneger1, E. Mikhnevitch, M. Seitz2, J.-M.
More informationEditing file. Color code: Important in red Extra in blue. Autoimmune Diseases
Editing file Color code: Important in red Extra in blue Autoimmune Diseases Objectives To know that the inflammatory processes in autoimmune diseases are mediated by hypersensitivity reactions (type II,
More informationISSN X (Print) Former Senior Professor, Head Department of Medicine, Former In-Charge, Rheumatology Services, SMS Medical College, Jaipur
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 216; 4(2D):569-574 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationExpression and diagnostic utility of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis
Egypt J Pediatr Allergy Immunol 2014;12(2):71-76. Original article Expression and diagnostic utility of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis Background: Juvenile
More informationPart XI Type 1 Diabetes
Part XI Type 1 Diabetes Introduction Åke Lernmark Epidemiology Type 1 diabetes is increasing worldwide and shows epidemic proportions in several countries or regions [1]. There is evidence to suggest that
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2012, 3 (4):408-412 Diagnostic Biomarkers in Rheumatoid arthritis An update Harpreet Kaur 1 and Jagmohan Singh 2 ISSN: 0976-8688
More informationInt.J.Curr.Microbiol.App.Sci (2016) 5(2):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 2(2016) pp. 338-343 Journal homepage: http://www.ijcmas.com Original Research Article doi: http://dx.doi.org/10.20546/ijcmas.2016.502.039
More informationAnti Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 65, No. 4, April 2013, pp 911 915 DOI 10.1002/art.37830 2013, American College of Rheumatology BRIEF REPORT Anti Carbamylated Protein Antibodies Are Present in Arthralgia Patients
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationStaging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationAlida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia
Alida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia Foreign molecules = antigens Immune response Immune system non-specific specific cellular humoral
More informationSerum anti-cyclic citrullinated peptide antibodies before and after treatment by disease-modifying anti-rheumatic drugs
Serum anti-cyclic citrullinated peptide antibodies before and after treatment by disease-modifying anti-rheumatic drugs Nasrin Moghimi 1, Feisal Farshadi 2, Mahin Lashkari 3, Ali Delpisheh 4, Abdorrahim
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationChapter 4. Advances in Rheumatology 2004 volume 2
Chapter 4 Sustained remission in a cohort of patients with rheumatoid arthritis: association with absence of IgM rheumatoid factor and absence of anti-ccp antibodies. Advances in Rheumatology 2004 volume
More informationDOI /art.39832
Letter to the Editor DOI 10.1002/art.39832 David Hutchinson MD 1 2, Daniel Murphy BmBs 1, Alex Clarke BSc 2 and Paul Eggleton MPhil, PhD 2 1 Department of Rheumatology, Royal Cornwall Hospital Trust, Truro,
More informationClinical Laboratory. [None
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG
More informationThe use of second generation anti-ccp antibody (anti-ccp2) testing in rheumatoid arthritis A systematic review
The use of second generation anti-ccp antibody (anti-ccp2) testing in rheumatoid arthritis A systematic review J.P. Riedemann 1, S. Muñoz 2, A. Kavanaugh 3 1 Department of Rheumatology and Clinical Epidemiology,
More informationDisclosures. Objectives. Inhaled risk factors for RA 11/7/2011. The Lung as a Site of Initiation of Rheumatoid Arthritis-related Autoimmunity
Disclosures The Lung as a Site of Initiation of Rheumatoid Arthritis-related Autoimmunity No conflicts of interest Kevin Deane, MD/PhD University of Colorado Rheumatoid Arthritis: Where Does it Begin?
More informationClinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/60699
More information